Here are the Lions Health winners in the health and wellness category.
WPP's Read: We're focusing on collaboration, rather than 'collapsing' agency brands and restructuring
Mark Read has warned against "collapsing" too many WPP agency brands and said driving greater collaboration is more important than a "major restructuring".
This year's Cannes Lions Festival will be different to any that preceded it - but then, it was always thus.
Quest Analytics buys BetterDoctor; Analyst Eric Schmidt to join Allogene Therapeutics; Two-thirds of Americans "very concerned" about cost of health insurance.
It's still entirely up to drugmakers whether they want to make their products available on an experimental basis. Patients may not see it that way.
FCB Health features heavily in a rising percentage of U.S. campaigns that made it to the Pharma Lions shortlist - the company's Rich Levy is jury president this year.
Collete Douaihy, Digitas Health's executive vice president, executive creative director shares advice for navigating Cannes, her opinion on the new schedule, and how she's handling judging.
Eli Lilly CEO says changes needed in drug pricing system; Kentucky sues Walgreens over opioid epidemic; Teva faces migraine drug setback.
The number of entries to Cannes Lions has dropped by 21.4% from last year, which organisers ascribed partly to Publicis Groupe's temporary withdrawal and partly to their decision to restructure the awards programme.
Rishi Shah stepped down from the chief executive position five months ago amid fraud allegations.
Two FDA guidance documents aim to help pharma companies show the value of their drugs to payers beyond what's included in FDA labeling.
BIO afterparty again sparks controversy; GSK meets goal for two-drug HIV treatment; Mylan receives complete response letter for Advair generic.
In the week that former WPP chief Sir Martin Sorrell faced claims of bullying behaviour and paying for a prostitute, the ad group will be breathing a sigh of relief after an AGM that avoided a showdown.
The WPP agency is hoping its reorganization results in more collaboration among health and wellness staffers.
Drugmakers not dropping prices on Trump timeline; Azar backs insurance for those with preexisting conditions; Stryker denies interest in Boston Scientific takeover.
WPP faced tough questions about Sir Martin Sorrell's exit at its annual general meeting, with more than a quarter of WPP shareholders voting against his entitlement to a possible $26.7 million pay-off.
For the first time, the nonprofit is trying to eliminate bans on gay and bisexual men donating blood in countries other than the U.S.
WPP joint COO Mark Read has emailed all staff at the group to tell them to expect respect from their colleagues and announce a group-wide code of conduct review.
FDA puts Sage depression treatment on accelerated timeline; AstraZeneca, Lilly cease Alzheimer's treatment trial; Stryker makes offer for Boston Scientific.
Martin Sorrell's reputation is under increasing fire from the press, with both the 'Financial Times' and the 'Daily Mail' using their front pages to air allegations about his conduct today.
Eckert returns to lead Sprout Pharmaceuticals; Sorrell denies prostitution allegation; AHIP warns about removing key Obamacare provisions.
WPP's unpublished investigation into its former chief executive Martin Sorrell's conduct examined whether he used company funds to pay a prostitute, according to reports.
The creative director of Sudler Australia shares her opinion on changes to Cannes' scheduling and how she's preparing for long days spent judging.
WPP investors are set to lodge a significant protest over Sir Martin Sorrell's pay-off but executive chairman Roberto Quarta is expected to survive.
Novo Nordisk considers cutting 3,000 jobs; Pharma companies pressured to move birth control over the counter; Gates Foundation launches a nonprofit biotech.
Former JWT global chief executive Gustavo Martinez has departed WPP in a sign that the ad group's new leadership wants to draw a line under his controversial tenure.
Women healthcare leaders discussed the gender pay gap and tools for women to advocate for themselves on stage at MM&M's Hall of Femme event Thursday.
Life and career lessons from Novartis' Vanessa Thirion-Cullity and other executives.
The State of Diversity in Healthcare Marketing: For years, pharma has talked about diversity and inclusion issues in its midst, with some pundits saying the industry was slow to embrace diversity and others claiming that it's ahead of the curve.
Bayer closes Monsanto deal after lengthy antitrust review; Bezos, Dimon, Buffett pick CEO to run healthcare venture; Novartis to avoid criminal actions over Cohen payments.
Pillo's voice-activated robot will be studied among those 50-plus with diabetes. The robot uses facial recognition and can respond HIPAA-compliantly to questions.
The CEO of Ogilvy CommonHealth North America shares advice for first-time attendees at Cannes.
Athenahealth CEO steps down; Former Celgene chief executive wins New Jersey Senate primary; Big Pharma not planning campaign against Trump drug pricing plan.
Investor pressure is likely to force WPP into selling Kantar, possibly along with other assets - which could open opportunities for Sir Martin Sorrell's new vehicle S4 Capital.
Just after the launch of Marcel, Publicis chief executive Arthur Sadoun was bombarded with questions from a packed room of clients, staff, and journalists.
AstraZeneca VP, head of U.S. oncology, Olivier Nataf details how being a company lifer impacted his career.
Two touted products in the pipeline reflect three of medical marketing's most profound modern-era challenges.
Medical science liaisons are essential participants in most aspects of the commercialization process.
Medicare Part D brand-name drug costs up even as prescriptions fall; Gottlieb could speed up approval process for competitors of first-to-market drugs; FDA approves Filphila.
Ogilvy is ditching Mather, introducing a new corporate identity and cementing months of streamlining with a simplified organizational structure that chief executive John Siefert says will "build a new model for our industry".
Meet "the connectors" as four of the best-regarded medical science liaisons and the leader of the MSL Society discuss what they do, how they do it, and why their work is so vital.
MM&M asked the pharma marketing community at large, via social media and other efforts, to provide its POV on equality, diversity, and inclusion.
Mark Stenhouse, president of Cologuard at Exact Sciences, shares his wake up routine and how he manages a busy schedule.
Although analysts predict this dynamic won't last long.
New study finds early-stage breast cancer may not need chemo; Merck's Keytruda succeeds in more studies; Athenahealth CEO faces allegations of inappropriate behavior
MM&M and Publicis Health debut results of their first Diversity Survey, detailing areas where healthcare agencies are progressing with regard to diversity and inclusion. Pharma leaders interviewed by MM&M say there are signs the industry is finally getting it right.
Its campaign arms patients with questions to ask their doctors before they're prescribed an opioid.
Opioid prescriptions drop for fifth year in a row; AstraZeneca reprimanded by U.K. regulator; Samsung partners with Babylon to bring appointments to smartphones.
A UK drug regulator has ruled that a 2017 press release from AstraZeneca was "misleading" as data "had not been presented in a balanced way", following a complaint from a fellow pharma firm.
The Quit Big Tobacco campaign from Vital Strategies is using HP's agency diversity push as a guide.
The website is part of Teva's rebranding efforts, which began in March.
FDA approves first artificial iris; Trump expects voluntary drug price cuts; Novartis' head of oncology departs.
"Creativity in 2018 comes from everywhere" Cannes Lions' outgoing chairman says, describing what's new this year and how it differs from his first ever Cannes in 1986.
The former Publicis Groupe chief executive provides a word of advice (literally) to Sir Martin Sorrell on life "post-CEO", as well as the right time to retire and life with a beard.
The story behind Sanofi's tweet: 'Using our medicines as a crutch for bad behavior is not appropriate'
Why Sanofi felt "obligated" to respond to Roseanne Barr's claim of "Ambien tweeting."
The drugmaker clapped back to Roseanne Barr's comment that she was "Ambien tweeting" when she made racist remarks about Valerie Jarrett.
Allergan to sell women's and infectious disease units; Large clinical trials falling out of favor; American Cancer Society recommends earlier screening for colon cancer.
Sir Martin Sorrell has confirmed details of his return to the front line of advertising only weeks after leaving WPP, with the launch of a new "multinational communication services business".
Legalization of the drug for medical use is already having an impact on prescription patterns. But for patients and doctors alike, there are a lot of unanswered questions.
The former WPP CEO is thought to be gearing up to acquire a new company which he will turn into a new marketing group.
MIT researchers develop ingestible sensor to detect intestinal bleeding; Diet Madison Avenue goes dark after defamation suit filed; Justice Department report finds Purdue knew about potential for OxyContin abuse.
As deepening healthcare forays by tech and e-commerce giants ratchet up the pressure on pharma to become more consumer friendly, drugmakers are still defining their new role.
Research from EvaluatePharma predicts the orphan drug market will grow 11% each year until 2024.
Specialist media consulting firms and media agencies have claimed Accenture faces a "clear conflict" of interest over the launch of its programmatic media planning and buying unit.
AstraZeneca lung cancer drug meets key goal; Johnson & Johnson loses another talc lawsuit; Cancer drugs account for 80% of drug sales.
As of May 25, Europe's groundbreaking General Data Protection Regulation (GDPR) will take effect, fundamentally changing the way businesses and government agencies deal with personal data.
Sun Pharma's branded prostate cancer treatment Yonsa just received FDA approval.
Publicis Groupe unveiled its much-anticipated AI-powered platform Marcel at its VivaTech event this morning in Paris.
Recro non-opioid injection receives complete response letter from FDA; Pfizer settles False Claims Act allegations; Medtronic reports better-than-expected profit.
Insys founder John Kapoor has maintained his innocence in the face of charges.
Stuart Ingis on the benefits of showing the public how advertisers and marketers use data and creating a global regulatory framework.
Speakers at the Coalition for Healthcare Communication conference discussed how regulations from the White House and FDA have affected healthcare comms.
Accenture has taken another big step into the agency space by launching a programmatic media planning and buying unit.
Keytruda passes late-stage trial; Astellas to cut 600 jobs in restructuring; Teva expects FDA decision on migraine drug by mid-September.
Nanobiosym hired the agency shortly after its proprietary technology was approved by the FDA.
Geisinger looks to expand DNA sequencing program; Celgene invests $65 million more in Evotec; Oscar launches transparency push.
Plan D: Experts predict government savings, but higher co-pays with Trump plan for lowering drug prices
The White House's strategy calls for moving expensive treatments from under Medicare Part B to Medicare Part D.
The Beating Cancer Is in Our Blood brand positioning was developed with Oberland.
FDA approves AstraZeneca potassium drug; Nabriva pneumonia treatment meets Phase III endpoints; "Bad Blood" hits bookshelves.
MM&M is honoring 15 of the most-senior women in healthcare along with 20 Women to Watch who are changing the industry.
MM&M is honoring 20 Women to Watch, aspiring healthcare commercial and marketing execs changing the face of the industry.
First preventative migraine treatment approved; NIH investigates funding for alcohol study; Trump to block federal funding for abortion clinics.
Shaun Qualheim from Amazon Web Services explained how the company's small teams and customer-first and failure-friendly culture promotes innovation.
Experts on using technology to change patient behavior and other topics.
At MM&M's annual conference, panelists talked about how healthcare is moving toward value-based care and accelerating innovation
Digital health experts discussed how tech is disrupting the healthcare industry at the MM&M Transforming Healthcare conference.
The president of the Biden Cancer Initiative shared lessons learned from the White House Cancer Moonshot.
Biden Cancer Initiative chief gets Transforming Healthcare conference started; Former Novartis CEO on Cohen payments; J&J's Gorsky has advice for Trump on drug pricing plan.
A divisive figure, Sorrell's rise to the top of the ad industry was never dull. Here, we outline the key moments.
Califf spoke about the importance of more data to faster and cheaper drug development at the NewYorkBIO conference.
For one of President Trump's proposals for lowering the cost of drugs, the path to implementation could be long.
Read the May 2018 issue in its entirety.
As WPP faces break-up calls in the wake of Sir Martin Sorrell's exit, the agency holding company model is under greater scrutiny than at any time since the 1980s.
Novartis' top lawyer exits after Cohen payments; More states file suit against Purdue Pharma; J&J to relaunch baby line.
Whether jurors will award a pharma Grand Prix, and whether US pharma will show up, are two open questions in the run-up to Lions Health.
Shields will serve as president of the Think Patients subsidiary firm.
Feds join whistleblower case against Insys; Kleiner Perkins Caufield partner Seidenberg departs; Lilly strikes second acquisition deal in a week.
To say that Sir Martin Sorrell's rapid departure from WPP was a seismic event is an understatement. So just what happened in the days leading up to the fall of its CEO?
Pharma stocks were up after the President went easy on drugmakers.
Beam Therapeutics raises $87 million in Series A funding; Trump drug-pricing plan largely spares big pharma; Novartis regrets Cohen consulting pact.